As vice chancellor for research protections at the University of Pittsburgh, I lead the team responsible for ensuring that our researchers comply with the substantial federal and state regulations surrounding fetal tissue research. This includes ensuring that the very option of donating fetal tissue for research is not discussed until a medical procedure has been confirmed.

Fetal tissue research can be a political and deeply emotional topic. It’s also seriously misunderstood, irreplaceable and effective. In 2020, every one of the top 10 National Institutes of Health funded institutions — Pitt included — received NIH grants for projects undertaking fetal tissue research. Leading biomedical research institutions continue to use fetal tissue today because it is so valuable in treating and curing diseases.

Studies involving fetal tissue helped us to develop the polio vaccine, as well as new treatments for cancer, diabetes, heart disease, rheumatoid arthritis and more. At Pitt, researchers have also studied tissue from stillborn children to understand what can go wrong during a pregnancy and how medical teams can help mothers have healthy babies.

Despite all the scientific advancements we’ve made, many diseases continue to threaten the American public. In 2020, the Alzheimer’s Association estimated that 5.8 million Americans were living with the disease — a number that will jump by more than 20% by 2025. The Journal of Parkinson’s Disease has reported that the number of Parkinson’s cases doubled between 1990 and 2015 and will likely double again — with 12 to 17 million Americans affected — by 2040. And, just last year, the Centers for Disease Control and Prevention predicted that the nation’s annual number of cancer cases would rise 49% by 2050.

Advertise with us

These diseases impact millions of Americans — and there are no guarantees that any one research method will lead to a breakthrough. That is why we must continue to use every tool available to us.

Much of the controversy linked to fetal tissue research is rooted in objections to abortion. I do not dismiss these opinions, but I do want to be clear: Having a medical procedure and donating the tissue obtained from it for research are two totally separate decisions. Research teams have no role in obtaining consent to donate tissue. Because of this, as state Rep. Dan Frankel noted in his Feb. 17 letter to the editor, “Preventing this research would not stop abortions; it would only stop medical advancements.”

Nationwide, there are groups advancing disinformation campaigns about fetal tissue research, including the false claim that it is an unnecessary, even for-profit undertaking. The fact is that right now there is no substitute for human fetal cells and tissue when it comes to studying certain aspects of disease and human development. These cells and tissues that adapt and grow in labs permit researchers worldwide to learn how human biology reacts in a unique and irreplaceable way.

This research is for scientific gain, for improving and saving life — only.

Both Pennsylvania law and the NIH definitively prohibit anyone from making a profit from gathering, storing, cataloging or conveying fetal tissue donations. Humanity profits, nobody else.

Advertise with us

Unfortunately, misconceptions and falsehoods have made their way into the public debate, leading people to believe that this work is unregulated and unnecessary.

But, as someone on the frontlines of overseeing this research, let me be clear: All research at the University of Pittsburgh is conducted in compliance with all relevant laws and regulations. Even more, these studies are primarily funded by federal grants that are subject to intense scrutiny. The university understands the importance of being transparent about this work, and why it is invaluable to Pitt scientists, medical innovation and patients everywhere.

We simply cannot allow misrepresentations of our research to stand in the way of a better future.

Bill Yates, Ph.D., is vice chancellor for research protections; professor of otolaryngology and neuroscience; and vice-chair of the School of Medicine Curriculum Committee at the University of Pittsburgh.